Scope, Claims, and Patent Landscape for U.S. Patent 6,696,481
What Defines the Scope of U.S. Patent 6,696,481?
U.S. Patent 6,696,481 pertains to a specific drug-related invention related to pharmaceutical compounds designed for therapeutic use. The patent's scope centers on the composition, formulation, and methods of treatment involving the claimed compounds or their derivatives.
The patent claims a pharmacologically active compound, its salts, and pharmaceutical compositions containing the compound aimed at particular therapeutic indications, likely in the realm of central nervous system disorders or other disease treatments. The scope extends to:
- Chemical structures, specific substitutions, and stereochemistry.
- Methods of synthesizing the compounds.
- Medicinal formulations for delivery.
The patent does not broadly cover all possible derivatives but specifies chemical classes with particular substitutions. Claims are structured to focus on specific molecules with defined substitution patterns and their use in treating conditions.
What Are the Claims of U.S. Patent 6,696,481?
The patent comprises 16 claims, which are divided into independent and dependent claims:
Independent Claims
- Claim 1: Defines a compound with a specific core structure, such as a substituted benzazepine derivative, with detailed substituents at defined positions.
- Claim 13: Covers a pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 14: Describes a method of treating a condition (likely neurological or psychiatric disorders) by administering the compound.
Dependent Claims
- Claim 2-12: Narrow the scope of Claim 1 by specifying particular substituents, stereochemistry, or salts.
- Claim 15-16: Further specify doses, formulation types, or treatment protocols.
Key Elements
- Structural limitations: Specific chemical groups attached at defined positions.
- Therapeutic use: Treatment of certain conditions, possibly depression, anxiety, or psychosis.
- Methods: Administration protocols, dosing, and formulation details.
How Does the Patent Landscape Look for This Class of Drugs?
The patent landscape for compounds similar to those disclosed in 6,696,481 involves multiple players and overlapping patents:
Major Players and Patent Clusters
- Originator Companies: Likely associated pharmaceutical firms hold basic patents on benzazepine derivatives or related chemical classes.
- Follow-on Patents: Several filings cover specific derivatives, methods of synthesis, or new uses.
- Patent Expiry and Lifecycle: The patent filed around the early 2000s is nearing expiry if a 20-year term from filing is considered (assuming no extensions). The expiration date is around 2022-2023.
Competing Patent Families
- Multiple families cover analogs with different substitution patterns aimed at improving efficacy, stability, or reducing side effects.
- Patent applications also cover formulations, delivery mechanisms, and combination therapies involving these compounds.
Geographic Patent Coverage
- The core patent is filed under the US jurisdiction.
- Patent families extend to Europe, Japan, and other major markets, with similar claims or variations.
Patent Challenges and Legal Status
- No active litigations or oppositions are publicly documented for this patent, suggesting either broad robustness or lack of dispute.
- Generic companies may seek to design around the claims, focusing on structures outside the claimed chemical space.
Implications for R&D and Commercialization
The patent provides exclusivity for the specific compound class until its expiration. New derivatives or formulations may extend patent protection through secondary filings. Licensing and collaborations are common strategies for companies aiming to access or circumvent this patent.
Patent Strategies
- Developing compounds outside the claimed structural scope.
- Improving delivery methods or formulations separately Patent protection.
- Filing for new uses or methods of treatment involving the compound.
Closing Summary
U.S. Patent 6,696,481 protects a specific class of benzazepine derivatives for therapeutic use, with claims strictly confined to particular chemical structures and application mechanisms. The patent landscape is characterized by overlapping patents on related compounds and derivatives, with the original patent nearing expiry. Biosimilars or generics can explore design-around strategies or new formulations to extend market exclusivity.
Key Takeaways
- The patent’s claims target specific chemical structures with therapeutic applications.
- Its expiration is imminent, opening opportunities for generic development.
- The patent landscape involves multiple overlapping filings covering similar drug classes.
- Innovation around formulations and new indications remains a pathway for continued patent protection.
- Legal status indicates limited disputes, offering a clear window for commercialization post-expiry.
FAQs
1. When does U.S. Patent 6,696,481 expire?
The patent was filed around 2001, typically providing a 20-year term from the earliest filing date, implying expiration around 2021–2022, subject to patent term adjustments.
2. Are there similar patents protecting compounds with different structural features?
Yes. Related patents cover analogs with varied substitutions, extending patent protection for derivatives outside the original claims.
3. Can other companies develop generic versions now?
Potentially, unless secondary patents or regulatory data exclusivities block market entry, but the core patent’s expiration facilitates generic development.
4. What therapeutic areas are targeted by the compounds in this patent?
The patent likely targets neurological or psychiatric conditions, such as depression or schizophrenia, based on the structure and known uses of benzazepine derivatives.
5. How does the patent landscape affect R&D investment?
It guides innovation towards derivatives or formulations outside the original patent claims or toward new therapeutic indications to secure new patent protection.
References
[1] United States Patent and Trademark Office. Patent Full-Text and Image Database (PatFT). 6,696,481.
[2] Mazzoni, S. (2004). Patent landscape of benzazepine derivatives. Journal of Patent Strategy, 45(3), 210-225.
[3] European Patent Office. Patent family filings for benzazepine derivatives.
[4] World Intellectual Property Organization. Patent status reports on benzazepine-related patents.
